IndraLab

Statements

Ruxolitinib inhibits IFNB1. 4 / 4
| 4
reach
"Ruxolitinib blocked these IFN-beta anti-inflammatory effects, implicating JAK signaling."
37799272
reach
"Our results showed that IFN-β effects were mediated by JAK signaling pathway-dependent activation, since IFN-β effects were inhibited by ruxolitinib."
37799272
reach
"As a control, we showed that 5 μM ruxolitinib blocked the ability of IFN-β to inhibit HCoV-229E infection ( Supplementary Fig. S5 )."
37805057
reach
"The results also show that Ruxolitinib (JAK inhibitor), prevented the effects of IFN-β on the decrease of α-SMA expression levels ( Fig. 3 A)."
33160814